Gossamer Bio updates seralutinib Phase 3 plans and 1-for-80 reverse split
Gossamer Bio said it reported positive Phase 3 PROSERA results for seralutinib in PAH, plans an NDA for September 2026, targets an FDA decision in Q3 2027, and completed a 1-for-80 reverse split effective Sept 10, 2026 while reducing authorized shares to 50M.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.